Liver Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1.Age >=18 years; 2.Patients diagnosed with unresectable HCC according to China's liver cancer diagnosis and treatment guidelines through clinical or pathological diagnostic criteria; At least one measurable tumor lesion confirmed by enhanced computed tomography or magnetic resonance imaging based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST); 3.Patients who have completed liver and spleen stiffness measurements, complete blood count, liver function tests, abdominal ultrasound or abdominal CT scans, and alpha-fetoprotein (AFP) tests; 4.Outpatient/hospital visit records or telephone follow-up duration >=1 year.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1.Patients with concurrent function failure of vital organs such as heart, lung, or kidney; 2.Patients with confirmed diagnosis of malignant liver tumors or malignant tumors in other sites; 3.Patients who have undergone splenectomy or those with imaging findings indicating splenic vein thrombosis; 4.Patients with a history of autoimmune diseases, hypothyroidism or hyperthyroidism, or asthma requiring treatment; 5.Patients with a history of allogeneic organ transplantation, including those who have undergone liver or kidney transplantation; 6.Patients with incomplete clinical or follow-up information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spleen Stiffness;Gastroscopy;Carvedilol;observe whether TACE/HAIC treatment is performed for liver cancer;To observe whether liver cancer is treated with combined immune targeted therapy.;Abdominal imaging examination (CT,MRI,B-ultrasound);Hepatocellular carcinoma marker; | — |
Secondary
| Measure | Time frame |
|---|---|
| PLT;Liver reserve function; | — |
Countries
China
Contacts
Guizhou Provincial People's Hospital